While most senior executives who responded to a recent Devex survey aren’t aware of the debate on randomized controlled trials or have no opinion, 70 percent of those who do believe the tool is overhyped.
This story is forDevex Pro subscribers
Unlock this story now with a 15-day free trial of Devex Pro.
With a Devex Pro subscription you'll get access to deeper analysis and exclusive insights from our reporters and analysts.
Start my free trialRequest a group subscription Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro subscribers may share up to 10 articles per month using the Pro share tool ( ).
Mario is a former senior development analyst at Devex's survey and advisory services team. Prior to Devex, Mario was a researcher for the Boston Consulting Group in Boston, Massachusetts, where he supported client engagements in a variety of sectors, including public sector, global health and the social impact space, among others. Before joining BCG, Mario earned his master’s degree in global affairs from New York University.
